Posted by Michael Wonder on 29 Apr 2019
Express Scripts excludes Lilly's new low cost insulin generic
27 April 2019 - Express Scripts excluded from its 2019 formulary Eli Lilly's newly launched generic insulin product, reinforcing the idea that PBMs want bigger rebates, not cheaper drugs.
PBMs and insurance companies typically require manufacturers pay rebates to secure inclusion or a favourable position on formularies.
The biopharma industry has argued that high list prices are required to make large rebates possible, increasing out-of-pocket costs for beneficiaries because co-insurance payments are based on list prices.
